Sector: Pharmaceuticals

Latest content

Inside the Brand Finance Global 500:  the 2021 winners and losers, and the outlook for 2022

As brands emerge into the post-pandemic world, Brand Finance’s David Haigh provides a high-level view on a historic year and an informed perspective with which to confront an unpredictable future global landscape

03 March 2022

New Thai Copyright Act passed; GSK Consumer Healthcare reveals rebrand; WIPO adjusts Madrid fees – news digest

In our latest round-up, we look at INTA announcing a new chief representative officer for Europe, Apple being ranked the most ‘relevant’ US brand, and much more.

25 February 2022

Sixteen key questions answered about Mexico’s cannabis brands landscape

Gloria Niembro and Arturo Revilla of Chevez Ruiz Zamarripa tackle the most pressing issues about cannabis-product trademarks in Mexico, a market set to go stratospheric if a new law allowing recreational use is passed

24 February 2022

WTR Brand Elite analysis: January 2022

Featured in Stock market performance

The WTR Brand Elite indices fell four points in the month ending 31 January, mirroring the performance of a number of major stock markets. Among the overall computing and software group, Microsoft dropped 27 points (albeit from a three-year high at the end of December) and Salesforce was down 20 points.

21 February 2022

High Court gives short shrift to request for stay of injunction for rebranding

In what may ultimately be perceived as a strategic coup ─ despite refusing a 21-week stay of injunction to facilitate rebranding by VAGISAN following a finding of infringement ─ the High Court has granted a three-week stay, pending the outcome of an application for permission to appeal

17 February 2022

Five challenges in branded generics – and how to overcome them

We go behind the scenes at Abbott to learn how to handle five of the biggest trademark challenges in one of the world’s most regulated industries.

07 February 2022

‘Hyal’ marks: General Court criticises EUIPO’s “contradictory” reasoning

The court found that the Board of Appeal’s decision relied on a contradictory assessment as to the understanding and perception of the word element ‘hyal’ by the relevant public.

01 February 2022

Triple blow for pharmaceutical company Kowa in dispute with generic drug manufacturer Krka

Kowa Company Ltd, the owner of the mark PITAVA in Class 5, suffered a series of defeats before the Hellenic Trademarks Committee and the Athens Civil Court of First Instance.

01 February 2022

Vetnique Labs partially successful in revocation action against GLANDEX mark

The controller referred to several decisions of the CJEU - including ANSUL and LA MER - setting out the requirements to establish genuine use of a mark insofar as revocation proceedings are concerned.

31 January 2022

Revocation of APIRETAL: the limits of the concept of ‘proper reasons’ for non-use

A trademark owner cannot invoke the existence of a specific regulatory framework to justify the non-use of a trademark which it has consciously registered for a wide range of goods.

24 January 2022

Unlock unlimited access to all WTR content